Professor Viktor Umansky
Group leader/Principal investigator
Skin Cancer Unit, German Cancer Research Center (DKFZ)
Dr. Umansky is professor of Oncology at the Faculty for Biosciences, University Heidelberg, Germany. He finished his PhD in 1982 at the Institute of Oncology (Kiev, Ukraine). Viktor Umansky is currently a leader of the group “Melanoma Immunotherapy” and Principal Investigator in Skin Cancer Unit at German Cancer Research Center (DKFZ) and University Hospital Mannheim (Heidelberg, Germany). His group is focused on the investigation of immunosuppression mechanisms and development of innovative immunotherapeutic strategies for human malignant melanoma using transgenic mouse melanoma model, which closely resembles human melanoma with respect to etiology, tumor genetics, histopathology and clinical development. Dr. Umansky is known for his work in the fields of i) nitric oxide-induced apoptosis of lymphoma cells, ii) anti-tumor reactivity of tumor antigen-specific memory T cells and iii) immunosuppressive activity of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). The group of Dr. Umansky made seminal contributions to the role of chronic inflammation and immunosuppression represented by MDSC in melanoma microenvironment and the development of strategies to overcome immunosuppression-induced by chronic inflammation in melanoma. Dr. Umansky has published around 150 papers in the field of immunology and oncology in peer-reviewed journals (including Nature Medicine, Nature Communications, Journal of Clinical Investigation, Blood, PNAS USA, Cancer Research, Clinical Cancer Research, OncoImmunology, Journal of Immunology etc.). He serves as a reviewer of manuscripts submitted in various peer-reviewed journals and of grants submitted to international foundations.